Skip to main content

Nonmucositis Mouth Lesions in Patients Being Treated for Cancer

  • Chapter
Oral Mucositis
  • 1578 Accesses

Abstract

Patients receiving cancer treatment, especially myelosuppressive chemotherapy, are at risk of developing oral lesions exclusive of mucositis. The most common are those associated with opportunistic mucosal infections and, in the case of allogeneic HSCT recipients, oral lesions of graft-versushost disease (GVHD). Lesion location, presentation and course are the key elements in making a correct diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sciubba JJ. Oral mucosal diseases in the office setting—Part 1: Aphthous stomatitis and herpes simplex infections. Gen Dent. 2007;55:347-354.

    Google Scholar 

  2. Sherman RG, Prusinski L, Ravenel MC, Joralmon RA. Oral candidosis. Quintessence Int. 2002;33:521-532.

    Google Scholar 

  3. Scully C, de Almeida OP. Orofacial manifestations of the systemic mycoses. J Oral Pathol Med. 1992;21:289-294.

    Google Scholar 

  4. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Rev. 2006; 20: 15-27.

    Google Scholar 

  5. Imanguli MM, Alevizos I, Brown R, et al. Oral graft-versus-host disease. Oral Dis. 2008;14:396-412.

    Google Scholar 

  6. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336-2347.

    Google Scholar 

  7. Sonis S, Treister N, Chawla S, et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116:210-215.

    Google Scholar 

  8. Sankhala K, Mita A, Kelly K, et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol. 2009;4:135-142.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Healthcare

About this chapter

Cite this chapter

Sonis, S.T. (2012). Nonmucositis Mouth Lesions in Patients Being Treated for Cancer. In: Oral Mucositis. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-46-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-46-7_8

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-63-0

  • Online ISBN: 978-1-907673-46-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics